跳至主要内容
临床试验/JPRN-UMIN000032723
JPRN-UMIN000032723已完成未知

Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertension - Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertension

agoya Universiy0 个研究点目标入组 50 人开始时间: 2018年5月31日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

sVEGF-A165b has the potential to detect LD-PH among the etiologies of PH, and sES may detect CTD-PAH in PAH. In addition, sES may be a marker to estimate the severity of PH. Because sES was correlated with the main items of the ESC risk table, sES is thought to reflect the severity of PH in recent treatment strategies. Further studies are needed in a treatment-naive cohort to verify the usefulness of sES.

研究设计

研究类型
Observational

入排标准

年龄范围
16years-old 至 90years-old(—)
性别
Male

入选标准

  • 未提供

排除标准

  • Diagnosis of malignant tumor Those already using pulmonary vasodilator (prostaglandin I 2 preparation, endothelin receptor antagonist, phosphodiesterase 5 inhibitor, stimulant of soluble guanylate cyclase)

研究者

发起方
agoya Universiy

相似试验